

GLOBAL HEALTHCARE EXECUTIVE SUMMIT

LUNCH &
CHECK-IN

11:30 - 12:30 pm Buffet Lunch (Ballroom/Lounge)

SPEAKERS & PANELISTS

12:20 - 12:40 pm

Welcome & Introduction

Banks Bourne, Bourne Partners

12:40 - 12:50 pm

Portfolio Spotlight: iNova Pharmaceuticals

Andrew Davis, iNova Pharmaceuticals

12:50 - 1:25 pm

Building Value in Pharmaceutical Services

Moderator: Jeremy Johnson, Bourne Partners

Panelists:

Roger Lias, Avid Bioservices, Inc.

George Svokos, *Formerly* Albany Molecular Research, Inc.

Stephen Trevisan, *Formerly* Accelovance, Inc.

Patrick Walsh, Avista Pharma Solutions

1:25 - 1:45 pm

Break #1

1:45 - 2:05 pm

Building and Monetizing in the PBM Sector

Introduction: Christopher Inklebarger, Bourne Partners

Speaker: Artemis Emslie, *Formerly* myMatrixx, LLC

2:05 - 2:25 pm

Capital Markets from the Driver's Seat

Introduction: Robert Stanley, Bourne Partners

Speaker: Andrew Callaway, Bank of America Merrill Lynch

2:25 - 3:00 pm

Building a Specialty Pharma Company

Moderator: Minor Hinson, Bourne Partners

Panelists:

Christopher Arington, Prasco Laboratories

Jack Davis, *Formerly* Covis Pharma, S.á.r.l

Kurt Orlofski, Pharmaceutical Associates, Inc.

3:00 - 3:20 pm

Break #2

3:20 - 3:40 pm

Global Health Equity

Introduction: Robert Keel, Tanner Pharma Group

Speaker: William Caldwell, Health Catalyst, Inc.

3:40 - 4:00 pm

Washington Healthcare Legislative & Regulatory Update

Introduction: Robert Stanley, Bourne Partners

Speaker: Andrew Bressler, Bank of America Merrill Lynch

4:00 - 4:20 pm

Culture Eats Strategy for Breakfast

Introduction: Xan Smith, Bourne Partners

Speaker: David Chapin, Forma Life Science Marketing

4:20 - 4:40 pm

503B Outsourcing: A Continuing Evolution

Introduction: Christopher Inklebarger, Bourne Partners

Speaker: Milton Boyer, SCA Pharmaceuticals, Inc.

4:40 - 5:00 pm

Break #3

5:00 - 5:20 pm

Trends in OTC/Cosmetic Dermatology

Introduction: Xan Smith, Bourne Partners

Speaker: Maria Carell, Revision Skincare & Goodier Cosmetics

5:20 - 5:50 pm

The Role of International Taxation in Healthcare

Moderator: Minor Hinson, Bourne Partners

Panelists:

Sean King, Align Global Consulting

Pieter van Tol, Weidema van Tol

5:50 - 6:20 pm

Fireside Chat with Paul Campanelli

Moderator: Banks Bourne, Bourne Partners

Speaker: Paul Campanelli, Endo International plc

COCKTAIL
RECEPTION

6:30 - 8:00 pm Networking Cocktail Reception (Pavilion Terrace)

GLOBAL HEALTHCARE EXECUTIVE SUMMIT

** listed by order of appearance*

Banks Bourne | Founder & Chief Executive Officer | Bourne Partners

As Founder and CEO, Banks oversees all business operations and direct investment opportunities at Bourne Partners. He and the firm have been party to more than \$10 billion of transactions in the pharmaceutical (“pharma”), pharma services, and consumer healthcare sectors. Banks is also the founder of Tanner Pharma Group, a pharma services company dedicated to providing managed access, commercialization, and clinical trials services to patients and partners in more than 100 countries.

For early 20 years, Bourne Partners has transacted with nearly all major pharmaceutical and specialty pharmaceuticals companies around the world, including Banks’ initial investment in King Pharmaceuticals in the late 1990’s. This investment introduced Banks to the pharmaceutical world and jumpstarted his interest in the healthcare sector. Since then, he has invested in more than 200 private companies / assets.

Prior to founding Bourne Partners, Banks held the position of Senior Vice President of Corporate Development for TITAN Technology Partners and worked in the investment banking field for Wachovia Securities, Inc. He received a B.A. degree in Business Management (Magna Cum Laude) from North Carolina State University and an M.B.A. from Wake Forest University. He is a member of Young Presidents Organization (YPO).

While Banks has derived great satisfaction by offering focused advisory services to, and investing in pharma, healthcare, and consumer-oriented companies that need strategic and operational insights, he is even more gratified by knowing that his work has helped companies to improve the health and well-being of patients across the world. Banks is passionate about providing healthcare and specifically pharmaceuticals to less fortunate patients, as demonstrated by supporting The Max Foundation, Partners in Health, The Bourne Foundation, The Levine Children’s Hospital, and other non-profit organizations.

Andrew Davis | Chief BD/M&A Officer | iNova Pharmaceuticals

Mr. Davis has served as the Chief BD/M&A Officer at iNova Pharmaceuticals since September 2017. Prior to iNova, Mr. Davis served as the Head of Oncology Business Development at Merck. Prior to Merck, Mr. Davis served as the SVP of Business Development at Valeant Pharmaceuticals, a global pharmaceutical, consumer products, and medical device company, leading all transactions for the company from 2014 to December 2016. Prior to this role, Mr. Davis had increasing roles of responsibility within the Business Development function at Valeant, joining the company in 2012. Prior to Valeant, he served as a management consultant at McKinsey & Co. focused on the healthcare space from 2007-2012.

Mr. Davis received his B.A. in Economics from Boston University in Boston, Massachusetts. He has completed over 60 transactions with an aggregate value of over \$30 billion.

Jeremy Johnson | Managing Director | Bourne Partners

Jeremy has 17 years of healthcare focused M&A and private equity experience. He has been with Bourne Partners since 2006 and is part of the core leadership team at the firm. Jeremy currently serves as a Managing Director, overseeing the broker dealer and all investment banking activities. He also leads a transaction team that drives much of the firm’s buy-side efforts for existing portfolio companies and new investment opportunities.

Prior to Bourne Partners, Jeremy was a founding member and Managing Director at Madison Keats, a life sciences strategy and consulting firm. Jeremy began his career at VentureWorx, an internet incubator. He is a graduate of Georgetown University where he earned a Bachelor of Arts in Economics.

Outside of work, Jeremy is very active in the community. He is a member of Leadership Charlotte and a supporter of both the Paula Takacs Foundation for Sarcoma Research and the Cystic Fibrosis Foundation (the “CFF”). A few years ago, Jeremy was honored by the CFF, being named their Standout Charlottean of the Year for his fundraising efforts. He remains very active with Georgetown University and is President of the local alumni club.

GLOBAL HEALTHCARE EXECUTIVE SUMMIT

Roger Lias | President & Chief Executive Officer | Avid Bioservices, Inc.

Roger Lias is President, Chief Executive Officer, and board member at Avid Bioservices, Inc. (NASDAQ:CDMO), a biologics contract development and manufacturing organization located in Tustin, CA. Roger has extensive experience in the biologics manufacturing space, including heading business development at both Lonza Biologics and Diosynth (now Fujifilm Diosynth), and as a member of the founding executive teams at KBI Biopharma and Cytovance Biologics.

He received a B.Sc. in Physiology and Biochemistry from Southampton University and earned his Ph.D. in Biochemistry at the University of Cambridge.

Having been a North Carolina resident for the past eighteen years, Roger is currently balancing a “bi-coastal existence” and is in the process of relocating his long-suffering wife and two teenage daughters to Southern California.

George Svokos | Former Chief Commercial Officer | Albany Molecular Research, Inc. (AMRI)

George Svokos joined AMRI in 2014 and was an instrumental member of the management team that redirected AMRI's direction and helped establish and implement a value-creating strategy for the company and its shareholders. Before joining AMRI, Mr. Svokos was with Teva Pharmaceuticals Industries Ltd. for more than 30 years, most recently as Senior Vice President, Product and Portfolio Selection and Business Development. Mr. Svokos was also Senior Vice President, U.S. Technical Operations, responsible for strategic planning, manufacturing, supply chain, regulatory, and legal compliance and safety, for 11 U.S. dosage form manufacturing facilities, as well as for supply of branded and generic products to the U.S. market from overseas plants in Europe, the Middle East, China, and India. Before that, he served as Executive Vice President of Teva API, having held various prior roles in that division of Teva.

Mr. Svokos earned a B.S. in Chemical Engineering from Columbia University in 1980 and an M.B.A. from the University of Missouri in 1995. He served as a Board Member of the Drug, Chemical and Associated Technologies Association (DCAT) from 2011 to 2017 and served as its President in 2015. He was a Trustee of the Dr. Agnes Varis Charitable Trust. He serves on the Board of Advisors of Pharmascience, Ltd.

Stephen Trevisan | Former President & Chief Executive Officer | Accelovance, Inc.

In 2004, Mr. Stephen J. Trevisan founded Accelovance, Inc., a CRO providing services to the biopharmaceutical industry with operations in the United States and Peoples Republic of China. He served as President and Chief Executive Officer through 2018, when the company was acquired by Asia-based CRO, Linal Co.

Mr. Trevisan co-founded his first company, National Clinical Research Centers (NCRC) in 1987. NCRC was a clinical Contract Research Organization (CRO) specializing in phase II-IV clinical studies and was sold in 1992. In 1994, he founded CommSys Corporation, a provider of outsourced billing services to the telecommunications industry. After two years of exceptional growth and profitability, the company was sold to Perot Systems. Mr. Trevisan remained with Perot in a leadership role in their Communication and Media practice until December of 1998 when he founded TherImmune Research Corporation (TRC). TherImmune was a CRO specializing in pre-clinical and early stage clinical drug development services for the pharmaceutical, biotech and government markets. The company was sold in April 2003 to Gene Logic Inc.

Mr. Trevisan holds a B.S. degree in Marketing from American University.

GLOBAL HEALTHCARE EXECUTIVE SUMMIT

Patrick Walsh | Chief Executive Officer | Avista Pharma Solutions

Patrick Walsh is CEO of Avista Pharma Solutions, a high-growth CDMO that provides pharmaceutical clients with a full suite of service offerings including analytical, microbiology, API, formulation, drug substance, and drug product manufacturing expertise and capabilities.

Prior to joining Avista Pharma, Patrick was CEO of AAIPharma Services, where he led its successful 4-year growth strategy that improved EBITDA by \$37 million and culminated in the company's sale for 4.6 times return on invested capital. Prior to that, he was President & COO of Gensia-Sicor, where he led the company's growth from \$24 million to over \$600 million and led to its eventual sale to Teva for \$3.2 billion. He also served as CEO of two biotechnology organizations. Earlier in his career, he led U.S. & international business activities for Fujisawa USA.

Patrick also currently serves as an Operating Partner at Ampersand Capital, a private-equity firm based in MA, and serves as an independent board member to Avid Bioservices in Tustin CA, ANI Pharmaceuticals in Baudette MN, and the UK-based contract service organization, MedPharm Ltd.

Christopher Inklebarger | Chief Operating Officer & General Counsel | Bourne Partners

As Chief Operating Officer and General Counsel at Bourne Partners, Chris Inklebarger oversees the firm's operations and strategy execution. He also spends time evaluating investment opportunities and working on select management consulting assignments. Chris heads up all of the firm's administrative and operational units, including; legal, marketing, accounting, IT, and HR. Chris also serves as the Chief Compliance Officer and AMLCO for Bourne Partners Securities, the firm's registered broker dealer. He has held various positions and roles within Bourne Partners and its affiliated companies throughout his career with the firm.

Chris received his B.S. from the University of Tennessee and earned a J.D. and an M.B.A. from the University of Tennessee College of Law and the Haslam College of Business. Prior to joining Bourne Partners, Chris worked with the Triple-A affiliate of the White Sox, the Charlotte Knights.

Artemis Emslie | Former Chief Executive Officer | myMatrixx, LLC

With 25 years of experience in both the workers' compensation and group health industries, Artemis Emslie brings a multi-dimensional perspective to the complex issues facing pharmacy benefit management (PBM) clients.

As CEO of myMatrixx, Artemis led the strategic growth of the company from a regional PBM focused on small to medium-sized clients to an industry leader with a national client base serving corporate and public sector groups of all sizes. After the company was sold to Express Scripts in 2017, Artemis oversaw the successful year-long transition to the workers' compensation division of the nation's largest PBM.

Prior to joining myMatrixx in 2012, Artemis held senior leadership positions with several companies before launching ProspeRx Solutions, an auditing firm for workers' compensation insurance providers where she provided PBM claims auditing, RFP management, and consulting services to several blue-chip clients.

Artemis founded and currently serves on the executive board of the Alliance of Women in Workers' Compensation, a think tank committed to sharing ideas and mentoring tomorrow's industry leaders. She also served as chairperson of the Workers Compensation Research Institute (WCRI) Core Funders Group. Currently, she serves on the board of directors for Paradigm Outcomes and Ametros, as well as on the advisory boards for the Cordant Health, Committee for Economic Development (Washington, D.C.), Business Insurance magazine, Kids' Chance, and the American Heart Association Circle of Red.

As a recognized industry expert, Artemis is a frequent speaker at national industry conferences on topics such as drug trends and best practices in pharmacy benefit management. She has been recognized as one of Business Insurance magazine's Women to Watch and honored with WorkCompCentral's Comp Laude Leadership and President's Honor Roll awards. Artemis is currently working with the University of South Florida's College of Pharmacy faculty to develop an academic program that combines pharmacy doctoral education with business entrepreneurship.

GLOBAL HEALTHCARE EXECUTIVE SUMMIT

Robert Stanley | Vice President | Bourne Partners

Robert joined Bourne Partners in 2010 as part of the healthcare investment banking team. He is responsible for supporting the firm's M&A assignments and private equity investments. He works directly with some of the firm's portfolio companies, helping with ongoing business development and deal execution.

Prior to Bourne Partners, Robert was an analyst at BB&T Capital Markets in the Structured Finance Investment Banking Group where he helped provide derivatives and securitization solutions for the firm's clients.

Andrew Callaway | Managing Director - Global Head of Life Sciences | Bank of America Merrill Lynch

Andrew Callaway is a senior member of the Life Sciences team in the Healthcare Corporate and Investment Banking Group at Bank of America Merrill Lynch. Andrew possesses nearly 20 years of investment banking experience and has advised on over 125 M&A and financing transactions in the biopharmaceutical sector.

Prior to joining Bank of America Merrill Lynch in the New York office in 2017, Andrew was the Global Head of Life Sciences Investment Banking at Wells Fargo and Deutsche Bank.

Andrew graduated from Amherst College. He is married with three children.

Minor Hinson | Senior Managing Director & Chief Investment Officer | Bourne Partners

Since starting at Bourne Partners in 2011, Minor has been responsible for direct investment activities and has been very involved in both the Phoenix Therapeutics, Inc. joint venture with The Carlyle Group, as well as with the creation, management, and asset disposition of Covis Pharma S.à.r.l ("Covis"). Minor also served on the Board of Covis from inception to exit.

Over the course of his career, Minor has been involved in over \$10 billion of financial transactions spanning the range of venture investing, private equity, mezzanine and senior debt, project finance debt and equity, cross border preferred stock issuances, sell-side and buy-side M&A transactions (both large cap and middle market), and other corporate finance advisory assignments. Minor has also served on the Board of Directors of a number of companies over his career.

Minor began his business career in 1984 in Corporate Banking at NCNB/NationsBank/Bank of America and became a Senior Relationship Manager in the Baltimore/Washington loan production office before deciding to attend business school in 1990. After an M.B.A. internship in corporate finance at The Coca Cola Company in Atlanta, Minor accepted a position as an Associate at Bowles Hollowell Conner & Company in Charlotte. Minor left Bowles Hollowell to co-found The McMillan Group with former U.S. Congressman Alex McMillan. Minor also worked as a Managing Principal at Piedmont Venture Partners. Minor returned to Bank of America in 2002 to join the Strategic Investment segment, a function he eventually managed. He was then recruited to manage Corporate Development for the bank's Global Treasury Services (\$4 billion in profit). In 2007, Minor decided to join Christofferson Robb & Company to raise capital and work on the initial London project team of the firm's offshore wind farm (Thanet Offshore Wind Limited).

Minor received a B.A. in Economics from Davidson College in 1984, as well as an M.B.A. (honor society) in 1992 from The Kenan-Flagler Business School at UNC Chapel Hill.

GLOBAL HEALTHCARE EXECUTIVE SUMMIT

Christopher H. Arington | Vice Chairman & Chief Executive Officer | Prasco Laboratories

Chris Arington is the Vice Chairman and Chief Executive Officer of Prasco, a privately held, generic pharmaceutical company located in Mason, Ohio.

As one of the founding members in 2002, Arington played a critical role in the development and strategy of the Authorized Generics business model. Serving as the CEO since 2011, Arington has been committed to the expansion of Prasco's role in the pharmaceutical industry through its relationships with over 50 of the most innovative pharmaceutical companies.

Prasco has maintained leadership in Authorized Generics by launching 89 products in 30 therapeutic categories, while providing patients with brand quality at more affordable prices in over 60,000 pharmacies nationwide.

In addition to his business pursuits, Mr. Arington supports multiple local and national charities that provide children access to healthcare, education, and athletics.

Jack Davis | Former Chief Executive Officer | Covis Pharma, S.à.r.l.

Jack Davis was a founder and the CEO of Covis Pharma S.à.r.l from 2010 - 2015. He worked with Bourne Partners to raise the initial \$80 million funding for the company. He proposed and worked with both local and international consultants to setup Covis' offshore legal and tax structure. He hired and managed Covis' offshore executive team and staff. He established an out-sourced business model by initiating relationships with pharma manufacturing, marketing, regulatory, tax, legal, and product distribution entities. He worked with Bourne Partners to identify and lead 6 successful product acquisition deals (including 4 with "Big Pharma" companies) over a 4-year period. He also met with financial institutions to raise \$250 million in debt to fund a large product portfolio acquisition.

Jack coordinated the development, approval, and launch of one product line extension - as well as the launch of 4 authorized generics. In consultation with pharma marketing consultants, he recommended select pricing actions for certain products. Finally, he helped coordinate the \$1.2 billion sale and transition of the majority of Covis' product line to Concordia Healthcare in 2015.

Jack has over 30 years of experience in the pharmaceutical industry including: marketing and sales; manufacturing, quality, and product supply; product development; regulatory; and business development.

Jack began his career with Price Waterhouse. He received a B.S. degree in Accounting from Wake Forest University in 1980. Jack and his wife Toni have 3 grown children and 2 grandchildren.

Kurt Orlofski | Chief Executive Officer | Pharmaceutical Associates, Inc. (PAI)

Kurt Orlofski, CPA, CMA, has been Chief Executive Officer of Pharmaceutical Associates Inc. since January 2017. A leader and turnaround CEO, Kurt has led generic pharmaceutical companies for over 20 years.

From 2009 to 2016, Mr. Orlofski was President and COO at G&W Laboratories. Prior to G&W, he was President of Wockhardt USA (Apr 2007 - Aug 2009). Prior to Wockhardt, he was President and Chief Executive Officer of Pliva, Inc., the US subsidiary of the global specialty pharmaceutical company, Pliva. He was responsible for all Pliva US businesses including 300 million USD of generics business. Previously, Mr. Orlofski was Senior Vice President of Global Business Development at Alkermes Human Pharmaceuticals. His areas of expertise include pharmaceutical general management, transformational leadership, operations and quality management, sales and marketing in generics, new business unit start-ups, product acquisition, brand and generic in and out licensing of products and technology, business unit and asset sales and acquisitions including integration, contract manufacturing deals in and out, and negotiation and execution of supplier, and customer supply agreements.

GLOBAL HEALTHCARE EXECUTIVE SUMMIT

Robert Keel | Director of Managed Access Programs | Tanner Pharma Group

Rob leads the Managed Access Programs division at Tanner Pharma Group and has held global general management and finance roles within the pharmaceutical, airline, and agriculture industries. He has a track record of developing innovative and disruptive distribution models and has lived and worked extensively across the EMEA and Asia Pacific regions. Within the pharmaceutical industry, Rob has previously been responsible for the management and operation of the EMEA commercial supply chain at AstraZeneca and led business development activities at UK-based Alliance Healthcare.

Rob holds an Industrial Engineering and Management Sciences degree from Northwestern University and an M.B.A. from Harvard Business School.

William Caldwell | Senior Vice President for Physician & Market Development | Health Catalyst, Inc.

Will Caldwell attended Davidson College where he prepared for a career in medicine, studying biology and working in East Africa as a wildlife manager. While living on a sailboat in Baltimore, Dr. Caldwell completed residency training in otolaryngology – head and neck surgery at the University of Maryland Medical System and the Shock Trauma Center of Maryland. He went on to achieve triple board certification in otolaryngology, allergy and immunology, and sleep medicine. In 2013, he became a board member and medical director of Give Hope Global, a not-for-profit entity dedicated to the development of health systems focused on the use of community health workers. They recently won two Emmy Awards for a documentary film about their work in Haiti.

Dr. Caldwell earned his M.B.A. from Wake Forest University and served as the Senior Vice President for Clinical Integration at Novant Health. He built the Novant Health Clinically Integrated Network, a value-based platform comprised of over 2800 providers across 26 specialties. In his current role as Senior Vice President for Physician and Market Development at Health Catalyst, he promotes the use of data analytics to promote good health and save lives. He continues to see patients and has received over 26 awards for clinical excellence during his 17-year career as a clinician.

Andrew Bressler | Managing Director | Bank of America Merrill Lynch Global Research

Mr. Andrew Bressler joined Bank of America in 1995. He provides analysis of trends, forecasts, legislative and regulatory impacts, and strategic directions for the healthcare industry. He works with both the fixed income and equity healthcare research teams, as well as the Bank's Healthcare Investment Banking team.

Before joining Bank of America, Mr. Bressler was director for policy and research at the National Institute for Health Care Management, where he focused on healthcare legislation and healthcare market trends.

Prior to helping form the National Institute for Health Care Management, Mr. Bressler was an associate in the Strategy Practice of Mercer Management Consulting.

Mr. Bressler received an M.B.A. from the University of North Carolina at Chapel Hill. He also received an M.S. and a B.S., from the University of Michigan.

GLOBAL HEALTHCARE EXECUTIVE SUMMIT

F. Alexander (Xan) Smith | Managing Director of Business Development | Bourne Partners

Xan is responsible for Bourne Partners' business development activities, with a focus on M&A, capital raising, licensing and partnering opportunities within the firm's pharmaceutical, pharma and healthcare services, and consumer health-focused investment banking advisory practice.

Xan Smith began his career in corporate banking at Wachovia Securities. Prior to Bourne Partners, he worked in investment banking at First Union Capital Markets where he was responsible for corporate finance solutions for select industry and Fortune 1000 clients. Most recently, he served as a Director of Scale Finance LLC where he provided capital and strategic advisory solutions for companies in high growth sectors. His professional experience also includes extensive involvement in real estate development, both with large scale master planned community developer, Crescent Resources, LLC/Morgan Stanley Real Estate, and as a principal of The Fulton Group LLC.

Xan received a B.A. in English with a minor in Business from Wake Forest University (cum laude) and spent an academic year abroad at The University of St. Andrews, Scotland, where he was a member of the University golf team. He also received an M.B.A. degree from Wake Forest University with a concentration in Finance.

David Chapin | Chief Executive Officer & Co-Founder | Forma Life Science Marketing

For nearly 30 years, David has provided strategic and tactical marketing expertise in the pre-clinical and clinical research, drug development, medical device, and life science sectors. He has a keen understanding of scientific and medical concepts and a proven ability to translate them in ways that improve employee alignment and profit. These can be applied to communications of all types, including lead generation campaigns, content marketing and other thought leadership initiatives, websites, video, brochures, and more.

David presents to diverse audiences – from C-Suite executives, to researchers, to other technically sophisticated directors and managers – about the challenges of employee alignment and marketing/communication in the life sciences. His recent engagements include presentations about creating high-performance marketing for the North Carolina Center of Innovation, Virginia Bio, Charlottesville Business Innovation Council (VA), and MAGI East 2015 Clinical Research Conference. He has also taught and lectured at the Business/Innovation/Growth Council in Charlotte, NC, and several universities and colleges including the College of Design at North Carolina State University, the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill, UNC-Charlotte, East Carolina University, and Peace College. He was invited to speak at the South Carolina Arts Commission's first biennial, state-wide design arts conference entitled "Good Design is Good Business."

David is a board member of NC Bio and is the author of "Making the Complex Compelling: Creating High Performance Marketing in the Life Sciences," and has been published in Life Science Leader, Impact, and PharmaExec magazines, as well as MedAd News.

David has a master's degree in Product Design and a bachelor's degree in Physics with a minor in Mathematics.

Milton Boyer | Chief Executive Officer | SCA Pharmaceuticals, Inc.

Milton Boyer joined SCA Pharmaceuticals in September of 2017. Mr. Boyer has served in technical, commercial, and executive roles in the pharmaceutical industry for more than 25 years with a specific focus in contract manufacturing for both drug substance and sterile drug product. For the last 10+ years he has been prominently involved in sterile drug product manufacturing, serving as Head of Drug Product Manufacturing at Albany Molecular Research Inc., and President and CEO of Oso BioPharmaceuticals.

Mr. Boyer serves on the board of directors of the Drug, Chemical & Associated Technologies Association (DCAT) and is now on the executive committee as its President. He has also served on the external advisory board for the University of New Mexico's chemistry and biology department and has been an active member of other professional organizations, including the American Association of Pharmaceutical Scientists, the Parenteral Drug Association, and the Society of Chemical Manufacturers and Affiliates. Mr. Boyer has a bachelor's degree in Chemistry/Physics from Hardin-Simmons University and a master's degree in Biochemistry from Texas Tech University.

GLOBAL HEALTHCARE EXECUTIVE SUMMIT

Maria Carell | President & Chief Executive Officer | Revision Skincare & Goodier Cosmetics

Maria Carell serves as President and CEO of Revision Skincare & Goodier Cosmetics. Both companies are owned by RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry.

Maria has an extensive background in operating, acquiring, and developing healthcare and life science companies, with a particular focus on pharmaceutical and medical device development. She was previously the CEO of Exeltis Inc., and has held Senior Executive roles at MEDA AB (NASDAQ OMX Large Cap List), and served as President and CEO of Q-Med (NASDAQ OMX Mid Cap List), and General Manager of Actavis Pharmaceuticals. She has also served in several business development, sales, and marketing roles for organizations ranging in size from small entrepreneurial to large cap global (Novartis, Johnson & Johnson). During her career, Maria has led organizations to substantial organic growth and guided additional growth through transformational acquisitions. She is also credited with the successful divestiture of Q-Med to Galderma S.A., a transaction valued at approximately 1 billion USD.

Maria has held several board assignments as Board Member and as Chairman of the Board in both public and private life science and health care provider companies. She is currently on the Board of Directors at Handicare AB, a global healthcare equipment company (NASDAQ OMX Mid Cap List). Maria has also been nominated for numerous awards such as the "Most Powerful Business Woman Award" and "Rising Talent" at the Global Women's Forum.

Maria holds a M.Sc. degree in International Business/Business Administration from Linköping University in Sweden.

Sean King | President & Managing Director | Align Global Consulting

With experience as a partner at a "Big 4" accounting firm and one of the world's largest law firms, Mr. King's highly regarded practice focuses on international tax planning for both the outbound operations of U.S. multinationals and the inbound operations of foreign multinationals. This includes advice on structuring mergers and acquisitions, internal restructurings and operations, joint ventures, cross-border financing, and transfer pricing matters, including the transfer and licensing of intellectual property. For twenty years, Sean has been counseling organizations ranging from emerging growth companies to one of the world's largest private equity firms with more than 40 billion USD under management.

Mr. King is a member of the State Bar of Michigan and is admitted to practice before the U.S. Tax Court. He is also a member of the North Carolina Bar Association where he has served as Vice-Chair of the International Law Section. Mr. King is the author of multiple publications on international taxation and is a widely-known speaker on the cross-border structuring of investments. In this capacity, Mr. King has been asked to speak worldwide for numerous Fortune 100 audiences and has been included in The International Who's Who of Corporate Tax Lawyers. He received his Master of Laws degree in taxation, magna cum laude, from the Chicago-Kent School of Law. He received his Juris Doctor degree, cum laude, from Michigan State University College of Law and his Bachelor of Arts degree from the University of Michigan at Ann Arbor.

Pieter van Tol | Resident Partner | Weidema van Tol

Pieter van Tol is a resident partner at Weidema van Tol, a firm providing international legal, taxation, and business advice. He is based in Zürich, Switzerland.

Pieter is recognized as an expert in the field of international corporate taxation. After graduating from Erasmus University in Rotterdam with a doctoral degree in fiscal Economics, he worked in the taxation department for Ernst & Young in The Hague and in London. In 1990, Pieter was appointed head of the worldwide tax department of the Leica Corporation (a multinational concern engaged with the manufacture and sale of measuring equipment and cameras) at their headquarters in St. Gallen, Switzerland. In 1992, together with Frank Weidema, Pieter established his own international corporate tax advisory firm. They built up a multinational corporate client base from their offices in Zürich, providing taxation, legal and management services to corporate clients, including names such as 3M, Bank of America, Dollar Tree, Equifax, Goodrich, Johnson Diversey, Lowe's, Marriott, McCormick, NRG Energy, Inc., Wachovia, and SunTrust, serving most of them for over 20+ years. As such, Pieter assisted clients through the full life-cycle of their structures, starting from their establishment, continuing with their day-to-day operations, and guiding them through tax audits, international, and domestic law changes.

GLOBAL HEALTHCARE EXECUTIVE SUMMIT



Paul V. Campanelli

President & Chief Executive Officer
Endo International plc

Paul V. Campanelli was appointed President, Chief Executive Officer, and a Director of Endo International plc effective September 23, 2016. Since assuming this leadership position at Endo, Mr. Campanelli has helped transform the organization with a vision to be a highly focused generics and specialty branded pharmaceutical company, delivering quality medicines to patients in need through excellence in development, manufacturing, and commercialization in the following business segments: U.S. Branded Pharmaceuticals, U.S. Branded Sterile Injectables, U.S. Generic Pharmaceuticals, and International Pharmaceuticals. Mr. Campanelli has led the company's strategic focus on organic growth through investments in hard-to-produce generic assets and technologies, a highly specialized branded business, and a concentration on differentiated and intelligent product selection.

Prior to joining Endo, he served as Chief Executive Officer of Par Pharmaceutical following the company's September 2012 acquisition by TPG. Prior to the TPG acquisition, Mr. Campanelli served as Chief Operating Officer and President of Par Pharmaceutical from 2010 to 2012. At Par Pharmaceutical, Mr. Campanelli also served as Executive Vice President, Business Development & Licensing; he also served on the Board of Directors of Sky Growth Holdings Corporation which was formed by investment funds affiliated with TPG Capital, L.P. As CEO, he led Par's \$490 million acquisition of Michigan-based JHP Pharmaceuticals, a specialty pharmaceutical company that develops, manufactures, and markets branded and generic sterile injectable pharmaceuticals. In addition, Mr. Campanelli led Par's \$410 million acquisition of California-based Anchen Pharmaceuticals, a specialty pharmaceutical company focused on extended release and niche generic products. He also spearheaded Par's acquisition of Edict Pharmaceuticals, an India-based developer and manufacturer of generic pharmaceuticals.

Mr. Campanelli began his career at Par in 2001 as Senior Director, Business Development and established Par's business development and licensing group. He was named Vice President, Business Development in 2002 and Senior Vice President, Business Development & Licensing in 2004. Throughout his tenure, Mr. Campanelli delivered numerous successful new product launches.

Prior to joining Par, Mr. Campanelli served as Vice President, Formulations Business Development at Dr. Reddy's Laboratories Ltd. where he was employed from 1992 to 2001.

Mr. Campanelli earned his Bachelor of Science degree from Springfield College.